Site last updated:
December 2011
Cancer Services Forum currently has 1452 registered members
Conference Reports
These consist of reports on key commissioning conferences, meetings or symposia.
The Editorial Advisory Board invites readers to send in reports from any relevant meetings for publication.
Recent Conference Reports include
Commissioning cancer care: report from the 2011 London Cancer New Drugs Group annual conference
0 comment on this article -
Be the first to comment
Welcome to the December 2011 issue of Cancer Services Forum.
The relevance of the London Cancer New Drugs Group (LCNDG) annual conference is validated by the high demand for places to attend the 2011 annual conference, the fifth such meeting. Registration was closed in August, confirming the popularity among clinicians, pharmacists, nurses, commissioners and other healthcare professionals. Although driven by the aims to facilitate consistency of approach in London by informing the managed entry of new drugs in cancer treatment and to promote the cost-effective and equitable provision of all medicines used in cancer, the topics discussed have relevance across the UK.
Improving access to new cancer medicines: report from the 2010 LCNDG annual conference
0 comment on this article -
Be the first to comment
Welcome to Cancer Services Forum—the final issue for 2010. It has been a whirlwind year in cancer services, and this edition of the forum, featuring a review of the London Cancer New Drugs Group (LCNDG) Conference 2010, is a great way to round it off.
The annual LCNDG Conference has become a “not to be missed” event for many of us, and this year’s meeting, held at the Novotel London St Pancras on 24th November, was no exception. In a climate of increasing uncertainty, sometimes bordering on hysteria and often fuelled by misinformation and disinformation, the LCNDG Conference provided a much-needed rational analysis of the current state of the economy, its impact on the NHS, and the continuing need for mechanisms to secure access to new cancer medicines. I hope you enjoy reading this comprehensive review of the event—I can personally attest that it is well accompanied by a mince pie (or two).
New cancer medicines: Joint working between the NHS and the pharmaceutical industry
0 comment on this article -
Be the first to comment
Closer working between the NHS and the pharmaceutical industry has been a key theme in cancer commissioning this year.
It also proved to be an important topic at the first national conference of the North of England Cancer Drugs Approval Group (NECDAG), where speakers from both camps discussed how they could work together to improve access to medicines for cancer patients. We bring readers a full report by Conference Chair, Steve Williamson.
Cancer Commissioning—at a global and a local level: London Cancer New Drugs Group Annual Meeting
0 comment on this article -
Be the first to comment
Another year, another outstanding London Cancer New drugs Group (LCNDG) annual meeting—and, as ever, a brilliant gathering of committed delegates to keep the presenters on their toes.
Patient-access schemes (PASs) dominated the proceedings, with lively discussions on, for example, risk-share, top-up payments and the emerging role of the PAS Liaison Unit (PASLU) part of the National Institute for Health and Clinical Excellence (NICE).
Read on for a full report on the talks from: Professor Adrian Newland, David Webb, Andy Stainthorpe, Dr Paul Catchpole, Helen Knight, Professor Christopher McCabe, Rod Griffiths, Nick Bosanquet, Dr Monica Desai and Dr Andy Mitchell plus lively discussion from the meeting.
Commissioning Cancer Drugs and Services. The London Cancer New Drugs Group Meeting
0 comment on this article -
Be the first to comment
The London Cancer New Drugs Group (LCNDG) conference was perfectly timed. Professor Mike Richards had just issued his recommendation that NHS patients should be allowed to pay for additional medicines, and the conference coincided with the week that saw reports on cancer therapy published by the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) and the National Chemotherapy Advisory Group Report (NCAG).
The agenda for the 2008 London Cancer New Drugs Group (LCNDG) meeting asked three key questions. How will chemotherapy fit into the broader “world class” NHS commissioning imperative? How is the role of health technology assessment (HTA) groups evolving? What are the factors that influence their decisions?
The London Cancer New Drugs Group Meeting 2008
0 comment on this article -
Be the first to comment
The first London Cancer New Drugs Group (LCNDG) conference held in March 2007 was a great success, particularly because it prompted a debate about how all partners in health care needed to work together to ensure a timely and equitable introduction of new cancer drugs. The second conference, in January 2008, was timed to allow discussion on the recently published Cancer Reform Strategy.
